Video

Session 8 : Rapid Review : Part 1

J K Singh, K.C.Lakshmaiah

Chairpersons :

Rapid Review : Part 2 by Shona Nag

1. Impact of radiotherapy on complications and patient-reported satisfaction with breast reconstruction: Findings from the prospective multicenter MROC study

Author: Jagsi R

Conference: 2016 SABCS S3-07

2. US Surgeons Snipe at UK's DCIS Trial, Who, in Turn, Cry Foul.LORIS TRIAL CONTROVERSY

Author: Melissa Pilewskie

Reference: Medscape, Oct 16 Daniel Rea

3. Expert Critiquie : Multicentric Breast Cancer: OK for Breast Conservation? Data show the surgery is feasible, with good oncologic outcomes

Author: Laura M. Spring

Reference: Medpagetoday review

4. Noncoding somatic and inherited single-nucleotide variants converge to promote ESR1 expression in breast cancer

Author: Swneke D Bailey

Reference: Nature Genetics 48, 1260–1266(2016)

5. Can surrogate pathological subtyping replace molecular subtyping? Outcome results from the MINDACT trial

Author: F Cardoso

Conference: 2016 SABCS PD7-01

6. Circulating Tumour Cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab

Author: J-Y. Pierga

Reference: Annals of oncology, October 18, 2016

7. Overall survival of patients with HER2-negative metastatic breast cancer treated with a first-line paclitaxel with or without bevacizumab in real-life setting: Results of a multicenter national observational study

Author: S Delaloge

Conference: 2016 ASCO Annual Meeting, Abstract 1013

8. Disease-free (DFS) and overall survival (OS) at 3.4 years (yrs) for neoadjuvant bevacizumab (Bev) added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC), for women with HER2 negative early breast cancer: The ARTemis trial

Author: HM Earl

Conference: 2016 ASCO Annual Meeting, Abstract 1014

9. Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)

Author: Dickler MN

Reference: Lancet Oncol. 2016 Dec 6. pii: S14702045 (16) 30631-3

10. Effect of progesterone receptor on outcome of women with breast cancer

Author: SS Dawood

Conference: 2016 ASCO Annual Meeting, Abstract 573